Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Completed · Phase 2

Conditions studied: Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal

In brief

This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the treatment of moderate to severe VVC.

Key facts

Study ID
NCT02971007
Run by
Matinas BioPharma Nanotechnologies, Inc.
People needed
137
Starts
2016-11-01
Expected to finish
2017-05-01
Last updated by the study team
2018-11-02

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.